Replacement of the constrained phenylalanine analogue 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic) in the opioid Dmt-Tic-Gly-NH-Bn scaffold by the 4-amino-1,2,4,5-tetrahydro-indolo[2,3-c]azepin-3-one (Aia) and 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one (Aba) scaffolds has led to the discovery of novel potent l-selective agonists (Structures 5 and 12) as well as potent and selective d-opioid receptor antagonists (Structures 9 and 15). Both stereochemistry and N-terminal N,N-dimethylation proved to be crucial factors for opioid receptor selectivity and functional bioactivity in the investigated small peptidomimetic templates. In addition to the in vitro pharmacological evaluation, automated docking models of Dmt-Tic and Dmt-Aba analogues were constructed in order to rationalize the observed structureactivity data.
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Conformationally constrained amino acids have found widespread application in search of novel peptidic opioid ligands with minored side-effects. [1] [2] [3] [4] [5] [6] [7] [8] Such residues, inducing enhanced receptor selectivity and affinity, can be subdivided in sterically (e.g., bmethylphenylalanine, b-methyltryptophan, b-methyl-2 0 ,6 0 -dimethyltyrosine) and covalently constrained derivatives [e.g., 2-aminotetralin-2-carboxylic acid (Atc), 2-aminoindane-2-carboxylic acid (Aic), 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic)]. 9 The Dmt-Tic scaffold 1, in particular, has been recognized as a firmly established template for opioid ligand design. 3, 4 Subtle changes in this scaffold have induced remarkable alterations in opioid receptor selectivity and/or activity, such as enhanced agonism, antagonism, or the acquisition of mixed activities at the opioid subtype receptors (i.e., l, d and j receptors). Replacement of tyrosine by Dmt (2 0 ,6 0 -dimethyl-L-tyrosine) markedly modified the pharmacological profile of numerous unrelated opioid ligands. 3, 10, 11 Next to the crucial impact of Dmt on opioid potency, the introduction of Tic into naturally occurring opioid li gands, [12] [13] [14] led to the conclusion that this conformationally restricted phenylalanine analogue was responsible for the receptor antagonism displayed by Tic-containing structures. Earlier work in our laboratory involved the replacement of Tic 2 in Dmt-Tic derivatives 1 by the dipeptidomimetic Aba-Gly (Aba: 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one). This substitution, yielding opioid ligands of type 2 ( Fig. 1 ), led to increased receptor selectivities as well as a d-to l-receptor affinity shift, relative to the reference Tic derivatives. 15 The main structural difference between the constrained aromatic residues Tic and Aba, consists of the allowed low energy conformations for the amino acid v 1 space.
The Tic residue allows g(À) and g(+) conformations (v 1 = À60°and +60°, respectively), whereas Aba limits the side chain orientation to g(+) and trans (v 1 = 60°and 180°, respectively). 16 The same dihedral angles are favoured in the 4-amino-indolo[2,3-c]azepin-3-one (Aia) scaffold which is present in 3. The heterocyclic core of 3 was recently successfully used for sst 4/5 selective somatostatin peptidomimetics. 17 In this work, two approaches were followed to change potency, selectivity or functional properties of the previously reported Dmt Aba-Gly analogues 2. 15 In the first approach, the role of charge in the discrimination of opioid receptor selectivity and bioactivity was investigated by the preparation and evaluation of Aba-Asp (negative charge) and Aba-Lys (positive charge) derivatives. In the corresponding Dmt-Tic analogues, the charge of the C-terminal part had substantial effect on d-selectivity and antagonism. 18 In a second approach, the effects of replacing the benzene ring in the Aba scaffold in 2 by an indole ring, to give 3, was investigated. This approach was motivated by the fact that, on the one hand, in the bioactive conformation of Tyr The reference structures for this work consisted of peptidomimetics 4 and 5 ( Fig. 2) . 15 Dmt-Tic-Gly-NH-Bn 4 displays a d over l selectivity (Table 1) , whereas l-opioid receptor binding is pre- (Fig. 4) . The Bn aromatic ring of compound 5 stacks with the Aba group of the ligand and forms a cation-pi interaction with the positively charged nitrogen atom of K5.39 27 of MOR (Fig. 4B) .
To obtain positively and negatively charged scaffolds, respectively, Aba-Lys 6 and Aba-Asp 7 derivatives were prepared according to previously reported methods. 15, 36 The presence of a positive charge in ligand 6 seemed to be detrimental for binding to the active sites of both l-opioid and d-opioid receptors, as witnessed by a 22-to 26-fold decrease in affinity ( Table 1 39 The mean ± SEM values of three to six repetitions are based on independent binding assays conducted in duplicate using five to eight grade doses of peptides with several different synaptosomal preparations. b Agonism was expressed as IC 50 obtained from dose response curves. 40 These values represent the mean ± SEM of at least six fresh tissue samples. Deltorphin C and dermorphin were the internal standards for MVD (d-opioid receptor bioactivity) and GPI (l-opioid receptor bioactivity) tissue preparations, respectively. c Data taken from Ballet et al. 15 NA, not active (>20,000 nM); NT, not tested. . According to our docking model, this affinity loss in MOR of compound 8 compared to 5 can be ascribed to the elimination of the favourable cation-pi interaction between the C-terminal benzyl group in 5 and the positively charged amine group of K5.39, and the loss of stabilizing intramolecular pi-pi stacking between the Aba and Bn rings (Fig. 4B) . The N,N-dimethylation of Dmt-Tic sequences was initially introduced to develop more stable structures, as Tyr-Tic and DmtTic peptides are prone to form diketopiperazines. 3 The N,N-dimethyl analogue of 8, ligand 9, shifts receptor selectivity from the l-to the d-opioid receptor and concomitantly converts the activity profile, creating a d-opioid receptor antagonist, an effect that was also observed in Dmt-Tic analogues. ]EM-1 was determined to be a full agonist in the GPI and MVD assays, a loss in functional bioactivity was observed (IC l 50 = 223.8 ± 3.64 nM vs. 9.7 ± 2.21 nM for EM-1). 41 To further evaluate the constrained Aia template in opioid ligands, we prepared compounds 10 to 17 according to literature methodologies. 15, 41 The aminobenzazepinone moiety in the most active compound of the series, DmtAba-Gly-NH-Bn 5, was replaced by the Trp-counterpart Aia and yielded ligand 10 ( Table 1) . Both d-and l-opioid receptor affinities of 10 are situated in the moderate to high nanomolar range, while maintaining MOR selectivity. Only micromolar range potency was displayed when this structure was submitted to the functional GPI assay. The C-terminal ester equivalent of 10, compound 11, showed even less affinity for both l-and d-opioid receptors, and suggests the amide in 10 to be involved in hydrogen bonding and/or favorable directing of the terminal benzyl group. The substitution of the benzene ring of the Aba residue in 5 by the indole ring in 10 positions the benzene ring of the Aia residue further away from the MOR specific binding pocket between W7.35 and H7.36 ( Fig. 4B ), but also results in a slightly different orientation of the N-benzyl substituent, which may weaken the cation-pi interaction with the K5.39 residue of MOR. This is shown in the superpositions of the binding conformation of 5 and 10 in Figure 5 . The combination of both effects may explain the loss in binding affinity observed for 10 versus 5. 37 The comparison of ligands 15 and 17 clearly shows the crucial importance of stereochemistry in receptor binding efficiency.
In conclusion, of our two approaches to change the pharmacological profile of Dmt-Aba-Gly analogues, the one involving the introduction of both positive (Aba-Lys ligand 6) and negative (Aba-Asp ligand 7) charge proved to be detrimental for binding to and activation of the l-and d-opioid receptors, relative to the reference compound 5. This is in sharp contrast to previous observations in the Dmt-Tic series of analogues, where a positive charge in the side chain of the C-terminal amino acid considerably increased the l-affinity while maintaining d-affinity. A negative charge in these Dmt-Tic analogues was shown to be important for d-affinity, but prevented these ligands from interacting with the l-receptor.
18 These findings could be rationalized by the different binding modes that were observed for the receptor-docked structures between the Tic-containing versus the Aba-containing analogues. The C-terminal benzyl group in 5, on the other hand, was shown to be important for bioactivity at the MOR as demonstrated by the reduced potency of truncated ligand 8, a feature that was also rationalized by the binding mode of these ligands to the MOR.
In contrast, our second approach to investigate the importance of replacing the benzene ring in the Aba scaffold by an indole ring, which is equivalent to replacing a constrained Phe residue by a constrained Trp residue, resulted in some interesting new opioid ligands. The replacement of Aba in 5 by Aia in 10 resulted in a drop of affinity for both receptors however, the change of chirality to DAia in 12 resulted in a l-opioid receptor selective agonist with a potency comparable to the endogenous opioid endomorphin-1. The indole ring of Aia is therefore is more likely to mimic the Trp 3 residue in the l-agonist endomorphin-1 than the indole in the d-antagonist naltrindole. Finally, two novel N,N-dimethylated scaffolds 9 and 15 proved to be d-selective antagonists, which confirms that N,N-dimethylation of Dmt is able to induce antagonist properties.
18 Figure 5 . Superposition of the docking poses of compound 5 (blue) and compound 10 (red) in the MOR receptor model.
